Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Burlington
Elsevier Science
2011
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 |
| Beschreibung: | G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"? M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understandi |
| Beschreibung: | 673 pages |
| ISBN: | 9780123919137 0123919134 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043959907 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161213s2011 |||| o||u| ||||||eng d | ||
| 020 | |a 9780123919137 |9 978-0-12-391913-7 | ||
| 020 | |a 0123919134 |9 0-12-391913-4 | ||
| 035 | |a (ZDB-4-EBA)ocn763157847 | ||
| 035 | |a (OCoLC)763157847 | ||
| 035 | |a (DE-599)BVBBV043959907 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1047 |a DE-1046 | ||
| 082 | 0 | |a 615.19 | |
| 082 | 0 | |a 615/.19 | |
| 100 | 1 | |a Brody, Tom |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Clinical Trials |b Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| 264 | 1 | |a Burlington |b Elsevier Science |c 2011 | |
| 300 | |a 673 pages | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns | ||
| 500 | |a Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin | ||
| 500 | |a D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema | ||
| 500 | |a C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"? | ||
| 500 | |a M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control | ||
| 500 | |a C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug | ||
| 500 | |a Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understandi | ||
| 650 | 4 | |a Drug Evaluation | |
| 650 | 4 | |a Drugs / Testing | |
| 650 | 4 | |a Medicine | |
| 650 | 4 | |a Pharmacy | |
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a Clinical trials / Design |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Clinical trials |x Design | |
| 650 | 0 | 7 | |a Klinisches Experiment |0 (DE-588)4164223-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Klinisches Experiment |0 (DE-588)4164223-5 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029368611 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=453856 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=453856 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176916209467392 |
|---|---|
| any_adam_object | |
| author | Brody, Tom |
| author_facet | Brody, Tom |
| author_role | aut |
| author_sort | Brody, Tom |
| author_variant | t b tb |
| building | Verbundindex |
| bvnumber | BV043959907 |
| collection | ZDB-4-EBA |
| ctrlnum | (ZDB-4-EBA)ocn763157847 (OCoLC)763157847 (DE-599)BVBBV043959907 |
| dewey-full | 615.19 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 615/.19 |
| dewey-search | 615.19 615/.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05533nmm a2200601zc 4500</leader><controlfield tag="001">BV043959907</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161213s2011 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123919137</subfield><subfield code="9">978-0-12-391913-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0123919134</subfield><subfield code="9">0-12-391913-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn763157847</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)763157847</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043959907</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1047</subfield><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brody, Tom</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Trials</subfield><subfield code="b">Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Burlington</subfield><subfield code="b">Elsevier Science</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">673 pages</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"?</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understandi</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trials / Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trials</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinisches Experiment</subfield><subfield code="0">(DE-588)4164223-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Klinisches Experiment</subfield><subfield code="0">(DE-588)4164223-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029368611</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=453856</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=453856</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043959907 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:39:47Z |
| institution | BVB |
| isbn | 9780123919137 0123919134 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029368611 |
| oclc_num | 763157847 |
| open_access_boolean | |
| owner | DE-1047 DE-1046 |
| owner_facet | DE-1047 DE-1046 |
| physical | 673 pages |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Elsevier Science |
| record_format | marc |
| spelling | Brody, Tom Verfasser aut Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines Burlington Elsevier Science 2011 673 pages txt rdacontent c rdamedia cr rdacarrier G. To allow a period of adjustment of lifestyle of the study subjects, for example changes in dietary patterns Front Cover; Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, FDA and ICH Guidelines; Copyright Page; Contents; Acknowledgments; Preface; The Study Schema and Study Design; Intent to Treat Analysis; How to Choose the Endpoints; Diagnostic Tests; Mechanism of Action; Standards; Methodology; Clinicaltrials. Gov and other Registries for Clinical Trials; Introduction; Abbreviations and Definitions; Biography; 1 The Origins of Drugs; I. Introduction; II. Structures of Drugs; a. Origins of warfarin; b. Origins of methotrexate and 5-fluorouracil; c. Origins of ribavirin D. Origins of paclitaxele. Origins of cladribine; f. Origins of drugs in high-throughput screening; g. Origins of therapeutic antibodies; III. The 20 Classical Amino Acids; IV. Animal Models; a. Introduction; b. Estimating human dose from animal studies; 1. NOAEL approach; 2. MABEL approach; c. Scaling up the drug dose, acquired from animal studies, for use in humans; 2 Introduction to Regulated Clinical Trials; I. Introduction; II. Study Design; III. The Study Schema; a. Examples of schema from clinical trials; b. Sequential treatment versus concurrent treatment -- the Perez schema C. Neoadjuvant chemotherapy versus adjuvant chemotherapy -- the Gianni schemad. Neoadjuvant chemotherapy plus adjuvant chemotherapy -- the Untch schema; e. Forwards sequence and reverse sequence -- the Puhalla schema; f. Both arms received three drugs, each arm at a different schedule -- the Sekine schema; g. Staging -- the Blumenschein schema; h. Staging and restaging -- the Czito schema; i. Methodology tip -- staging; j. Decision tree -- the Baselga schema; k. Decision tree -- the Katsumata schema; l. Methodology tip -- what is "tumor progression"? M. Methodology tip -- unit of drug dose expressed in terms of body surface arean. Run-in period -- the schema of Dy; o. Methodology tip -- c-kit and imatinib; p. Run-in period -- the Hanna schema; q. How to maintain blinding of the treatment, when the study drug and the control treatment are provided by different-sized pills (or by different volumes of solutions) ... ; r. Methodology tip -- bevacizumab and VEGF; s. Dose escalation -- the Moore schema; t. Pharmacokinetics -- the Marshall schema; IV. Further Concepts In Study Design; a. Active control; b. Add-on design active control C. Three-arm study -- clinical trial with two different active control armsV. Summary; VI. Amendments to the Clinical Study Protocol; 3 Run-In Period; I. Introduction; a. Washout period; b. Detecting baseline adverse events; c. Excluding potential study subjects who have safety issues correlating with the study drug; d. To include only study subjects with controllable pain; e. To determine the maximal tolerable dose; f. To achieve and ensure steady state in vivo concentrations of study drug Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understandi Drug Evaluation Drugs / Testing Medicine Pharmacy MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Clinical trials / Design fast Medizin Clinical trials Design Klinisches Experiment (DE-588)4164223-5 gnd rswk-swf Klinisches Experiment (DE-588)4164223-5 s 1\p DE-604 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Brody, Tom Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines Drug Evaluation Drugs / Testing Medicine Pharmacy MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Clinical trials / Design fast Medizin Clinical trials Design Klinisches Experiment (DE-588)4164223-5 gnd |
| subject_GND | (DE-588)4164223-5 |
| title | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_auth | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_exact_search | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_full | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_fullStr | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_full_unstemmed | Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| title_short | Clinical Trials |
| title_sort | clinical trials study design endpoints and biomarkers drug safety and fda and ich guidelines |
| title_sub | Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines |
| topic | Drug Evaluation Drugs / Testing Medicine Pharmacy MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Clinical trials / Design fast Medizin Clinical trials Design Klinisches Experiment (DE-588)4164223-5 gnd |
| topic_facet | Drug Evaluation Drugs / Testing Medicine Pharmacy MEDICAL / Drug Guides MEDICAL / Nursing / Pharmacology MEDICAL / Pharmacology MEDICAL / Pharmacy Clinical trials / Design Medizin Clinical trials Design Klinisches Experiment |
| work_keys_str_mv | AT brodytom clinicaltrialsstudydesignendpointsandbiomarkersdrugsafetyandfdaandichguidelines |